Wolfgang Andreas Weber
#118,060
Most Influential Person Now
Researcher
Wolfgang Andreas Weber's AcademicInfluence.com Rankings
Wolfgang Andreas Webercomputer-science Degrees
Computer Science
#4671
World Rank
#4930
Historical Rank
Computational Linguistics
#495
World Rank
#503
Historical Rank
Machine Learning
#993
World Rank
#1008
Historical Rank
Artificial Intelligence
#1214
World Rank
#1236
Historical Rank

Download Badge
Computer Science
Why Is Wolfgang Andreas Weber Influential?
(Suggest an Edit or Addition)Wolfgang Andreas Weber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2014) (1949)
- Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) (1335)
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 (2009) (1255)
- Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging (2007) (778)
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. (2007) (774)
- Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography (2001) (546)
- Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. (2000) (515)
- Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. (2003) (508)
- Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD (2005) (494)
- Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. (2006) (459)
- Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. (1999) (458)
- Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. (2004) (456)
- Impact of animal handling on the results of 18F-FDG PET studies in mice. (2006) (453)
- Reproducibility of metabolic measurements in malignant tumors using FDG PET. (1999) (426)
- Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. (2001) (414)
- Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. (2001) (409)
- Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography (2001) (383)
- O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study (2000) (361)
- Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. (1998) (355)
- Use of PET for monitoring cancer therapy and for predicting outcome. (2005) (354)
- Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. (2004) (345)
- Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. (2003) (329)
- Tumor Cell Metabolism Imaging (2008) (316)
- FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings (2003) (315)
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT (2017) (310)
- [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. (2004) (306)
- Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man (2006) (303)
- Positron emission tomography as an imaging biomarker. (2006) (295)
- TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. (2008) (294)
- Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. (2005) (271)
- Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo (2015) (256)
- Assessing Tumor Response to Therapy (2009) (253)
- Biodistribution and Pharmacokinetics of the αvβ3-Selective Tracer 18F-Galacto-RGD in Cancer Patients (2005) (247)
- The EANM practice guidelines for bone scintigraphy (2016) (244)
- L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. (2005) (233)
- PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference (2011) (216)
- Anesthesia and other considerations for in vivo imaging of small animals. (2008) (213)
- Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. (1996) (212)
- An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. (2011) (210)
- Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors (2006) (205)
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study (2014) (191)
- Positron Emission Tomography for Radiation Treatment Planning (2005) (190)
- Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. (2001) (188)
- Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2018) (184)
- Breast imaging with fluorine-18-FDG PET: quantitative image analysis. (1997) (183)
- Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. (2006) (177)
- Quantitative F18‐fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign (2010) (176)
- Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas (2008) (176)
- Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. (2019) (173)
- Monitoring response to treatment in patients utilizing PET. (2005) (172)
- Relevance of Positron Emission Tomography (PET) in Oncology (1999) (169)
- Biological imaging in radiation therapy: role of positron emission tomography (2009) (166)
- Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis (2012) (166)
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible (2011) (163)
- FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas (2009) (163)
- Quantitative assessment of tumor metabolism using FDG-PET imaging. (2000) (159)
- [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism (2012) (157)
- Monitoring cancer treatment with PET/CT: does it make a difference? (2007) (143)
- PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. (2006) (141)
- Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study (2008) (140)
- Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. (2005) (140)
- Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer (2007) (138)
- O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes (2002) (138)
- Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas (2011) (137)
- First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting (2019) (131)
- Novel 64Cu- and 68Ga-Labeled RGD Conjugates Show Improved PET Imaging of ανβ3 Integrin Expression and Facile Radiosynthesis (2011) (131)
- Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men (2014) (130)
- Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non–Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort (2016) (128)
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine (2019) (127)
- Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy (2019) (126)
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
- Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. (2005) (122)
- Monitoring chemotherapy and radiotherapy of solid tumors (2006) (122)
- Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. (2012) (120)
- Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations (2000) (118)
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications (2012) (117)
- Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. (2006) (117)
- Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 (2019) (115)
- Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning (2008) (114)
- Molecular imaging in the development of cancer therapeutics. (2006) (113)
- Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. (2004) (111)
- Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. (2005) (111)
- Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. (2005) (110)
- Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas (2008) (108)
- 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer (2014) (108)
- Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors (2008) (107)
- Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction (2007) (107)
- Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. (2005) (105)
- Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors (2008) (104)
- Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients (2005) (104)
- Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. (2003) (104)
- Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET (2004) (103)
- Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. (1997) (103)
- 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma (2018) (103)
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments (2017) (101)
- [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. (2011) (101)
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. (2018) (98)
- Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. (2007) (97)
- PET for radiation treatment planning of brain tumours. (2010) (96)
- Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules (1998) (95)
- Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B (2011) (95)
- The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. (1998) (94)
- [German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]. (2011) (94)
- 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. (2006) (93)
- First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake (2016) (93)
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib (2011) (90)
- Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials (2015) (88)
- Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. (2016) (86)
- Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. (2008) (85)
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. (2020) (85)
- Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma (2008) (85)
- Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs (2008) (83)
- First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. (2000) (82)
- Imaging of tumor glucose utilization with positron emission tomography (2008) (82)
- Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells (2014) (82)
- Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies (2018) (82)
- Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. (2005) (82)
- Imaging of esophageal and gastric cancer. (2004) (81)
- Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. (2013) (80)
- Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years (2014) (80)
- Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. (2005) (80)
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer (2018) (78)
- Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. (2013) (76)
- Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83. (2011) (76)
- 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy (2012) (75)
- Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. (2002) (73)
- Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. (2015) (73)
- (18)F-labeled-bioorthogonal liposomes for in vivo targeting. (2013) (73)
- Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer (2017) (72)
- Consensus on molecular imaging and theranostics in prostate cancer. (2018) (70)
- Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. (1999) (70)
- Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy (2018) (68)
- Target engagement imaging of PARP inhibitors in small-cell lung cancer (2018) (67)
- Tumor angiogenesis targeting using imaging agents. (2001) (66)
- Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models (2016) (66)
- In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. (2018) (66)
- Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin (2013) (65)
- Radiotracer-based strategies to image angiogenesis. (2003) (65)
- Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. (2019) (63)
- FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. (2015) (61)
- Measuring response with FDG-PET: methodological aspects. (2009) (60)
- Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging (2014) (60)
- Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer (2017) (59)
- Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma (2015) (59)
- Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET (2016) (57)
- Molecular Imaging of Biomarkers in Breast Cancer (2016) (57)
- qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT (2019) (57)
- Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent (2016) (54)
- Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) (2016) (54)
- Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence (2020) (54)
- Molecular Imaging of Prostate Cancer. (2016) (53)
- 18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? (2007) (52)
- Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. (2009) (51)
- Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas (2001) (51)
- In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent (2014) (51)
- Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer Patients (2011) (51)
- Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome (2007) (50)
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan (2019) (50)
- Utility of PET in Breast Cancer. (1999) (50)
- Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. (2004) (48)
- PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging (2014) (48)
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2019) (47)
- Brown adipose tissue and nuclear medicine imaging. (2004) (47)
- In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. (2012) (46)
- Radioiodinated PARP1 tracers for glioblastoma imaging (2015) (46)
- Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen (2000) (45)
- CXCR4 antagonists suppress small cell lung cancer progression (2016) (45)
- Whole-body positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images (1997) (45)
- Monitoring Tumor Response to Therapy with 18F-FLT PET (2010) (44)
- Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. (2016) (44)
- European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. (2008) (43)
- FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients. (2019) (42)
- Use of the norepinephrine transporter as a reporter gene for non‐invasive imaging of genetically modified cells (2004) (42)
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. (2020) (41)
- Engineered Antibody Fragments with Infinite Affinity as Reporter Genes for PET Imaging (2008) (41)
- 3′‐deoxy‐3′‐[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma (2012) (39)
- Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? (2016) (39)
- Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer (2019) (39)
- Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study (2015) (39)
- Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT (2017) (38)
- Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist (2015) (38)
- PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma (2018) (38)
- Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanin PET (2012) (37)
- Role of radionuclide imaging in trials of antiangiogenic therapy. (2000) (37)
- Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors (2018) (37)
- Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. (2014) (36)
- Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice (2009) (35)
- Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist (2017) (35)
- Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. (2019) (35)
- How to study optimal timing of PET/CT for monitoring of cancer treatment. (2011) (35)
- PET for response assessment in oncology: radiotherapy and chemotherapy (2005) (35)
- Quantitative analysis of PET studies. (2010) (34)
- 18F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma (2013) (34)
- 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. (2007) (34)
- PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging avb3 Expression (2006) (33)
- Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques (2019) (33)
- Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients (2021) (32)
- PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer (2002) (32)
- Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview (2017) (31)
- Fluorodeoxyglucose-Positron Emission Tomography in Adenocarcinomas of the Distal Esophagus and Cardia (2003) (31)
- Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes (2018) (31)
- Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity (2020) (30)
- Does Imaging αvβ3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy? (2014) (30)
- Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer (2019) (30)
- Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling (2016) (30)
- Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. (1996) (29)
- Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 (2022) (29)
- PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer (2003) (28)
- The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma (2021) (28)
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer (2019) (28)
- FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas (2009) (28)
- Influence of experience and qualification on PET-based target volume delineation (2014) (28)
- Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. (2001) (27)
- Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. (2020) (27)
- 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (27)
- 18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism (2015) (27)
- PET/MR Imaging: A Critical Appraisal (2014) (27)
- FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
- T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target (2018) (26)
- 11C-Choline PET/pathology image coregistration in primary localized prostate cancer (2014) (26)
- Development of a clickable bimodal fluorescent/PET probe for in vivo imaging (2015) (26)
- Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma (2016) (26)
- 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo (2019) (25)
- The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST (2016) (25)
- Image Quality and Data Quantification in Dopamine Transporter SPECT: Advantage of 3-Dimensional OSEM Reconstruction? (2012) (25)
- Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04 (2021) (25)
- Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. (2015) (25)
- Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. (2019) (25)
- Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer (2018) (25)
- CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma (2020) (24)
- Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (2020) (24)
- Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas (2020) (24)
- Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. (2019) (24)
- Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (24)
- The Move from Accuracy Studies to Randomized Trials in PET: Current Status and Future Directions (2014) (24)
- Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma (2017) (24)
- Stereotactic ablative radiotherapy for small lung tumors with a moderate dose (2012) (24)
- The Controversial Linear No-Threshold Model (2017) (24)
- A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non–Small-Cell Lung Cancer (2015) (24)
- Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. (2017) (24)
- Activated Platelets in Carotid Artery Thrombosis in Mice Can Be Selectively Targeted with a Radiolabeled Single-Chain Antibody (2011) (23)
- FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus (2005) (23)
- Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed? (2014) (23)
- Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. (2021) (23)
- Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent (2017) (22)
- Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy (2016) (22)
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study (2022) (21)
- 18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer (2003) (21)
- The added value of PSMA PET/MR radiomics for prostate cancer staging (2021) (21)
- In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. (2011) (20)
- Joint Imaging Platform for Federated Clinical Data Analytics (2020) (20)
- Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial (2019) (19)
- Development of a New Folate-Derived Ga-68-Based PET Imaging Agent (2017) (19)
- Preferred transport of O-(2-[18F]fluoroethyl)-d-tyrosine (d-FET) into the porcine brain (2007) (18)
- Validation of a method for automatic image fusion of CT-data and C11-methionin-PET data for stereotactic radiotherapy using a LINAC (BrainLAB System). First clinical results (2002) (18)
- Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications (2020) (18)
- Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study (2018) (18)
- 2017 SNMMI Highlights Lecture: Oncology. (2018) (18)
- Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes (2020) (18)
- Trends in oncologic hybrid imaging (2018) (18)
- FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma (2014) (18)
- Amyloid-β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia (2013) (18)
- Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy (2017) (17)
- Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer (2018) (17)
- PET and SPECT for radiation treatment planning. (2012) (17)
- Metabolic Imaging Allows Early Prediction of Response to Vandetanib (2011) (17)
- Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. (2017) (17)
- Excretion of FDG into saliva and its significance for PET imaging (2002) (17)
- Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines (2019) (17)
- Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation (2020) (17)
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists (2018) (17)
- Chaperoning drug development with PET. (2006) (16)
- PET/CT molecular imaging in abdominal oncology (2004) (16)
- Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (2020) (15)
- Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? (2019) (15)
- An official ATS conference proceedings: advances in small-animal imaging application to lung pathophysiology. (2008) (15)
- PET/CT is a cost-effective tool against cancer: synergy supersedes singularity (2016) (15)
- Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53−/− Mice (2010) (15)
- Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib (2018) (15)
- Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. (2006) (15)
- How to use functional imaging information for radiotherapy planning. (2009) (15)
- Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (14)
- An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (14)
- A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas (2018) (14)
- Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome (2019) (14)
- UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 (2009) (13)
- Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria (2022) (13)
- Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells (2020) (13)
- 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series (2019) (13)
- Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men (2011) (13)
- Is There Evidence for Evidence-Based Medical Imaging? (2011) (12)
- The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts (2012) (12)
- Rates and equilibria for probe capture by an antibody with infinite affinity. (2010) (12)
- Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma (2019) (12)
- New tracers beyond FDG in head and neck oncology. (2011) (12)
- A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer (2020) (12)
- The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment. (2021) (12)
- Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models (2018) (12)
- Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial (2020) (12)
- Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer (2016) (12)
- Synthesis and Preclinical Evaluation of a 68 Ga-Labeled Adnectin, 68 Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression (2021) (12)
- First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer (2020) (11)
- PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial (2021) (11)
- Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression (2021) (11)
- First clinical evaluation of somatostatin receptor antagonist imaging (2010) (11)
- Positron‐emission tomography imaging in urological oncology: Current aspects and developments (2018) (11)
- 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts (2017) (11)
- Regional hyperthermia enhances mesenchymal stem cell recruitment to tumor stroma: Implications for mesenchymal stem cell-based tumor therapy. (2020) (11)
- [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. (2012) (10)
- Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb (2021) (10)
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy (2020) (10)
- Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T (2020) (10)
- Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A) (2016) (10)
- Neuronal Correlates of Clinical Asymmetry in Progressive Supranuclear Palsy (2014) (10)
- PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial. (2019) (9)
- Evaluation of the Efficacy of Targeted Imaging Agents (2016) (9)
- Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning (2021) (9)
- The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals (2020) (9)
- Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment (2020) (9)
- Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions (2021) (9)
- Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (9)
- Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. (2017) (9)
- O-(2-(18F)Fluorethyl)-L-Tyrosine Compared to L-(Methyl-11C) Methionine in Positron Emissions Tomography for Tumor Volume Delineation of Gliomas and Metastases (2005) (8)
- OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers (2017) (8)
- 11C-Choline Pharmacokinetics in Recurrent Prostate Cancer (2018) (8)
- Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis (2019) (8)
- Al18F labeling at room temperature of 2-aminomethylpiperidine-based chelators for PET imaging. (2019) (8)
- Small Data: A Ubiquitous, Yet Untapped, Resource for Low-Cost Imaging Innovation (2017) (8)
- Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer (2021) (8)
- Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma (2019) (8)
- Value of PET imaging for radiation therapy (2021) (8)
- Value of PET imaging for radiation therapy (2021) (8)
- Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy (2022) (8)
- Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts. (2018) (8)
- What Is the Clinical Value of PET/CT in the Diagnosis of Pulmonary Nodules? (2014) (7)
- Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. (2018) (7)
- 123I-Iodobenzamide SPECT Is Not an Independent Predictor of Dopaminergic Responsiveness in Patients with Suspected Atypical Parkinsonian Syndromes (2013) (7)
- Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial. (2004) (7)
- Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients (2021) (7)
- Selective sodium iodide symporter (NIS) genetherapy of glioblastoma mediatedby EGFR-targeted lipopolyplexes (2021) (7)
- Development of a chimeric Fab directed against human galectin-3 and validation as an immune-PET tracer for the sensitive in vivo imaging of thyroid cancer. (2020) (7)
- Clinical PET/MR. (2020) (7)
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer (2022) (6)
- A 3D Deep Residual Convolutional Neural Network for Differential Diagnosis of Parkinsonian Syndromes on 18F-FDG PET Images (2019) (6)
- Issues and controversies in nuclear medicine. Introduction. (2011) (6)
- Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer (2017) (6)
- Role of Molecular Imaging in the Era of Personalized Medicine: A Review (2014) (6)
- Driving the Future of Nuclear Medicine (2019) (6)
- Neuroimaging for Radiation Therapy of Brain Tumors (2019) (6)
- Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment (2021) (6)
- CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma (2019) (6)
- Room Temperature Al18F Labeling of 2‐Aminomethylpiperidine‐Based Chelators for PET Imaging (2020) (6)
- Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic (2021) (6)
- Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET (2007) (6)
- GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences (2014) (5)
- The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data (2021) (5)
- Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives (2020) (5)
- Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients (2020) (5)
- Effect of specific activity on the uptake of [68Ga]-DKFZ-PSMA11 in tumor and other organs (2016) (5)
- Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV (2015) (5)
- PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy (2021) (5)
- Prognostic Significance of Fluorodeoxyglucose Uptake in Non–Small Cell Lung Cancer. A Blurry Picture? (2007) (5)
- Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model (2020) (5)
- First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET (2020) (5)
- Influence of Animal Heating on PET Imaging Quantification and Kinetics: Biodistribution of 18F-Tetrafluoroborate and 18F-FDG in Mice (2017) (5)
- Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. (2019) (5)
- Hybrid Imaging of Peripheral Skeletal Disease by SPECT/High-Resolution Flat-Panel CT (2013) (5)
- Implementation of Cascade Gamma and Positron Range Corrections for I-124 Small Animal PET (2014) (5)
- Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (4)
- Using Monte-Carlo simulations to implement corrections for I-124 as a non-pure positron emitter in small animal and human PET imaging (2011) (4)
- Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer (2021) (4)
- Tracked 3D ultrasound and deep neural network-based thyroid segmentation reduce interobserver variability in thyroid volumetry (2021) (4)
- Influence of ROI definition on the results of FDG-PET studies in patients with sarcomas (2007) (4)
- PET and SPECT in Three-Dimensional Treatment Planning of Brain Gliomas (2000) (4)
- [Importance of FDG-PET/computed tomography in colorectal cancer]. (2019) (4)
- Assessment of hypoxia in esophageal carcinomas using 18F-MISO PET (2008) (4)
- Prognostic Value of metabolic parameters on Pretreatment F-18 FDG PET/CT in Patients with Advanced melanoma treated with Pembrolizumab (2019) (4)
- Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT (2022) (4)
- Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. (2006) (4)
- Monitoring of Tumour Glucose Metabolism by PET in a Phase I Study Evaluating Hormonal Therapy in Advanced Pancreatic Cancer (2002) (4)
- 18 F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma (2013) (4)
- Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) (2005) (4)
- 18 F-Meta Fluorobenzyl Guanidine (MFBG) PET imaging in patients with Neuroendocrine malignancies: Biodistribution, Pharmacokinetics, Organ dosimetry and Lesion uptake. (2016) (3)
- Imaging in Oncology Research (2011) (3)
- Dynamics of Tumor Hypoxia in Patients undergoing Radiochemotherapy for Head and Neck Cancer Evaluated with Serial 18F-fluoromisonidazole PET (2010) (3)
- Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome. (2016) (3)
- Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo (2021) (3)
- The value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography for the treatment planning of malignant gliomas. (1999) (3)
- Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer (2017) (3)
- Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (2020) (3)
- FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients. (2015) (3)
- Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients (2022) (3)
- A Historical Perspective on the Use of Radionuclides for Therapy (2013) (3)
- mutation and glucose metabolism in thyroid cancer patients : An 18 F-FDG-PET study (2015) (3)
- Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
- Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine (2012) (3)
- Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer (2022) (3)
- Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on 18F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer (2022) (3)
- 177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers (2022) (3)
- The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy (2022) (3)
- Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3 (2022) (2)
- Use of 68Ga-DOTA-TATE PET/CT for predicting the dose of 177Lu-DOTA-TATE therapy in patients with neuroendocrine tumors (NETs) (2012) (2)
- LETTER TO THE EDITOR: Reply from the Authors: (2003) (2)
- Noninvasive Imaging of A V B 3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib (2009) (2)
- PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK). (2022) (2)
- Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction (2008) (2)
- Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma (2022) (2)
- 2016 SNMMI Highlights Lecture: Oncology, Part 1. (2017) (2)
- RSV: Robotic Sonography for Thyroid Volumetry (2021) (2)
- In Vivo Testing of 177 Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer (2011) (2)
- Predictive value of interim PSMA PET during 177Lu-PSMA radioligand therapy for overall survival in patients with advanced prostate cancer (2019) (2)
- [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy]. (2020) (2)
- Monitoring neoadjuvant chemotherapy of bone and soft tissue sarcomas with FDG-PET/CT (2006) (2)
- Novel Low-Dose CT based Automatic Segmentation and Registration Framework for Liver Radioembolization Planning (2021) (2)
- Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard (2020) (2)
- SNMMI Highlights Lecture : Oncology (2017) (2)
- Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. (2020) (2)
- Mixed response on FDG PET/CT: Frequency and prognostic relevance in non-small cell lung cancer (NSCLC) (2014) (2)
- MO-DE-207B-11: Reliability of PET/CT Radiomics Features in Functional and Morphological Components of NSCLC Lesions: A Repeatability Analysis in a Prospective Multicenter Cohort. (2016) (2)
- Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies (2018) (2)
- A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). (2016) (2)
- Change in quantitative FDG-PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas (2007) (2)
- Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (2019) (2)
- Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma (2022) (2)
- Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. (2007) (2)
- Emerging molecular imaging targets and tools for myocardial fibrosis detection (2022) (2)
- Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA (2019) (2)
- Prognostic value of total lesion glycolysis on pretreatment F-18 FDG PET/CT in patients with advanced NSCLC treated with nivolumab (2018) (2)
- [18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response (2007) (2)
- Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study. (2021) (2)
- In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using 68Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages (2022) (2)
- Correction to: Value of PET imaging for radiation therapy (2021) (1)
- Comparison of SUVmax and SUVpeak for response assessment in stage 4 non-small cell lung cancer (NSCLC) by FDG PET/CT (2015) (1)
- Correction to: Value of PET imaging for radiation therapy (2021) (1)
- Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis (2022) (1)
- 89Zr-IAB2M minibody imaging in patients with prostate cancer: Biodistribution, kinetics, lesion uptake and organ dosimetry (2014) (1)
- Positron Emission Tomography: Significance for Preoperative N-Staging (2005) (1)
- Does the Injected Mass influence the Biodistribution of F-18-rhPSMA-7.3 on Positron Emission Tomography in Prostate Cancer Patients? (2020) (1)
- PET imaging of inflammatory processes during GvHD (2011) (1)
- 2694 : Delayed Administration of Growth Factors in a Mouse Model of Radiation-Induced Kidney Dysfunction (2006) (1)
- Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B cell lymphoma (DLBCL) measured by 18FLT-PET (2006) (1)
- Targeted imaging of NK1 receptor-expressing cancer with 64Cu-labeled new NK1 ligand (2015) (1)
- Tracked 3D ultrasound and deep neural network-based thyroid segmentation improve accuracy and interobserver variability in thyroid volumetry (2021) (1)
- First clinical evidence that radiolabeled somatostatin receptor antagonist may be preferable to agonists for the treatment of neuroendocrine tumors (2012) (1)
- Inhibitor-functionalized ultrasmall nanoparticles and methods thereof (2017) (1)
- Quantification of PSMA expression in primary human and xenograft tumors using radioligand binding and digital autoradiograpy (2015) (1)
- Nuclear Molecular Imaging of Cardiac Remodeling after Myocardial Infarction (2022) (1)
- 18F-rhPSMA7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy (2019) (1)
- Metabolic imaging predicts response and prognosis in neoadjuvant treated, locally advanced gastric cancer: Final results of a prospective study (2007) (1)
- Are radiolabeled GLP-1 receptor antagonists useful for scintigraphy? (2009) (1)
- 305 TUMOR HYPOXIA IN HEAD AND NECK CANCER DURING RADIOCHEMOTHERAPY EVALUATED WITH SERIAL [18F] -FLUOROMISONIDAZOLE PET (2012) (1)
- The value of IMT-SPECT investigation in the target volume definition of brain gliomas (1998) (1)
- Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors (2022) (1)
- 2016 SNMMI Highlights Lecture: Oncology, Part 2. (2017) (1)
- Reply: Eliminating Use of the Linear No-Threshold Assumption in Medical Imaging (2017) (1)
- 7037 POSTER Radiopeptide Therapy of Prostate Cancer LU-177-RM2 (BAY 1017858) Monotherapy and in Combination With PKI Inhibitors (2011) (1)
- Improved PET Imaging of a n b 3 Integrin Expression and Facile Radiosynthesis (2011) (1)
- F-18 FDG PET/CT for monitoring immunotherapy with PD-1 blockade in patients with advanced melanoma (2019) (1)
- A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
- Molecular imaging: dream or reality? (2001) (1)
- Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines (2019) (1)
- Validation of a method for automatic image fusion (BrainLAB System) of CT-data and C11-Methionin-PET data for stereotactic fractionated radiotherapy using a LINAC (2001) (1)
- Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis. (2018) (1)
- Value of PET imaging for radiation therapy (2021) (1)
- Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (1)
- Diagnostic performance of different quantitative and qualitative parameters and their combined value for the diagnosis of aortic graft infection using [18F]-FDG PET/CT (2019) (1)
- The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation (2022) (1)
- Contrast improvement of FDG microPET studies by voxel-wise Patlak analysis (2010) (1)
- Prognostic Impact of Early and Late 18fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Prior to Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed or Refractory Hodgkin Lymphoma (2011) (1)
- Utility of Amino Acid PET in the Differential Diagnosis of Recurrent Brain Metastases and Treatment-Related Changes: A Meta-analysis (2022) (1)
- Evaluation of insulin-like growth-factor-1 as a protective agent against radiation-induced kidney dysfunction in C3h mice: A dose-finding study (2004) (1)
- FDG-PET for radiation treatment planning in patients with lung metastases (2010) (1)
- Toward Novel [18F]Fluorine-Labeled Radiotracers for the Imaging of α-Synuclein Fibrils (2022) (1)
- Performance of automatic Liver Volumetry for Selective Internal Radiotherapy (2021) (1)
- Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. (2023) (1)
- 2388 : Non-Invasive Imaging of Alpha-v-Beta-3-Expression in Head-and-Neck Cancer Patients With (18F)Galacto-RGD and Positron Emission Tomography (2006) (1)
- Non‐invasive determination of the αvβ3 integrin expression using [18F]galacto‐RGD and pet (2001) (1)
- Translational molecular imaging. (2004) (1)
- Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy (2022) (1)
- Evaluation of metabolic imaging for assessment of tumor response to mTOR inhibitors (2007) (0)
- Quantitative FDG-PET is more accurate than CT size at differentiating malignant from benign peripheral nerve tumors (2008) (0)
- Interobserver variability of assessment of tumor response by FDG-PET (2007) (0)
- Introduction of semi-automatic whole-body tumor burden assessment in 68Ga-PSMA-11 PET/CT to predict outcome of PSMA-targeted radiologandtherapy (2018) (0)
- PP69. Cost effectiveness of FDG-PET in the evaluation of solitary pulmonary nodules (1997) (0)
- Multi-Reader Evaluation of Manual Tumor Delineation for Recurrent Glioblastoma on FET-PET Scan: Impact of PET Windowing Settings (2014) (0)
- Multimodality imaging of cytostatic response to therapy in tumor-bearing mice (2007) (0)
- Early prediction of response in patients with NSCLC stage III and IV during platin based chemotherapy by FDG-PET (2001) (0)
- Abstract 3735: Somatostatin receptor-based imaging and treatment of murine pancreatic neuroendocrine tumors induced by MEN1-loss (2018) (0)
- Differential Diagnosis of Parkinsonism with Deep Metabolic Imaging Biomarker – An Artificial Intelligence-Aided Multi-Cohort FDG PET Study (2020) (0)
- Prospects for Molecular Imaging in Humans (2005) (0)
- Using siRNA as a tool to dissect the molecular pathway for FDG uptake in tumor cells (2007) (0)
- PD17-04 DIAGNOSTIC EFFICACY OF 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR N-STAGING OF PATIENTS WITH HIGH RISK PRIMARY PROSTATE CANCER (2019) (0)
- Change of clinical management through serial FDG-PET/CT in patients with FDG-positive adverse events under immunotherapy (2019) (0)
- 68Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression (2021) (0)
- PSMA-ligand PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy: matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 (2019) (0)
- EP-1313 PET-BASED GTV CONTOURING: WAYS FOR IMPROVEMENT OF THE INTER-OBSERVER VARIABILITY IN MANUAL CONTOURING (2012) (0)
- 129 The impact of I-123-alpha-methyl-tyrosine spect in the planning of 3-D radiation treatment of brain gliomas (1999) (0)
- Effect of HNSCC Radiochemotherapy on Imaging Biomarker T2* MRI and its Relation to FMISO-PET Derived Hypoxia (2018) (0)
- [18F]FDG-PET is an early predictor of overall survival in patients with suspected atypical parkinsonian syndromes. (2015) (0)
- Reply: Radioguided Surgery (2021) (0)
- Metabolic response-guided treatment individualization in neoadjuvant therapy of locally advanced adenocarcinoma of the esophagogastric junction (AEG) (2007) (0)
- Treatment of Benign Meningiomas with Stereotactic Fractionated Radiotherapy (2005) (0)
- Makes the Difference (2011) (0)
- A compartmental model for kinetics of 64Cu-RGD peptide in mice (2008) (0)
- Supporting Information for Dual Modality Optical / PET imaging of PARP 1 in Glioblastoma Journal : Molecular Imaging and Biology (2015) (0)
- Dual-modality imaging and quantification of GLP-1R positive insulinoma and pancreatic beta-cell mass using a bimodal PET/fluorescence exendin-4 peptide (2014) (0)
- PH-0719: 18F-FDG-PET/CT parameters as predictors of survival and response to nCRT in esophageal cancer (2020) (0)
- Local recurrence after radical prostatectomy and additive radiation – can PSMA-radioguided surgery prolong therapy-free survival? (2020) (0)
- SP 112 Integration of metabolic imaging (PET CT) into clinical trials (2011) (0)
- Lack of association between striatal dopamine receptor availability and cerebral glucose metabolism in PSP (2010) (0)
- Glucagon-like peptide-1 receptor SPECT/CT for the preoperative localization of benign insulinomas (2012) (0)
- Target engagement imaging of PARP inhibitors in small-cell lung cancer (2018) (0)
- PO-0793 EXPERT PANEL REVIEW OF FDG-PET/CT IN NSCLC: IMPROVEMENT OF INTER-, INTRAOBSERVER VARIABILITY BY HARMONIZATION (2012) (0)
- 15O-H2O-PET analysis of blood flow in esophageal cancer (2008) (0)
- Radiopeptide therapy of prostate cancer with a bombesin antagonist combined with vasculature targeted photodynamic therapy (2014) (0)
- Tumor FDG-uptake after the initial cycle of chemotherapy and histopathologic response to neoadjuvant therapy in high-grade soft tissue sarcomas (2008) (0)
- External in-house validation of a prediction nomogram estimating pre-test 68 Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy (2020) (0)
- Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance (2015) (0)
- 2017 SNMMI Highlights Lecture: Oncology, Part 2. (2018) (0)
- Reproducibility of FDG microPET, Firefly and Renilla luciferase bioluminescence imaging measurements in tumor bearing mice (2006) (0)
- IMT-SPECT in brain gliomas: correlation with survival and consequences for irradiation treatment planning (2001) (0)
- Cerenkov luminescence imaging for radiation dose estimation of a 90Y-labeled GRPr antagonist (2014) (0)
- Imaging of regional cerebral glucose metabolism is superior to assessment of striatal dopamine D2/D3 receptors for the differential diagnosis of parkinsonism: A prospective PET and SPECT study (2012) (0)
- Inside Cover: From In Situ to In Vivo: An In Situ Click‐Chemistry‐Derived Carbonic Anhydrase II Imaging Agent for Positron Emission Tomography (ChemMedChem 1/2013) (2013) (0)
- High resolution reconstruction of whole body FDG PET studies (2012) (0)
- Breast I maging W ith P ositron E mission T omography a nd Fluorine-18 F luorodeoxygluco se: U se a nd L imitations (2000) (0)
- Inhomogeneous PET/CT-FDG response to therapy in metastatic breast cancer (2014) (0)
- Influence of animal heating on PET imaging quantification and kinetics: results on the biodistribution of 18 F-tetrafluoroborate and 18 F-FDG in mice (2016) (0)
- In situ click chemistry approach for the identification of carbonic anhydrase II and cyclooxygenase-2 PET imaging agents (2006) (0)
- 103 poster: Use of FDG-4D-PET-CT for the Delineation of Radiotherapy Target Volumes in Malignant Lung Lesions (2010) (0)
- Unexpected sensitivity of SST2 antagonists to radiometal modifications (2012) (0)
- Noninvasive Imaging ofavb3 Integrin Expression Using F-labeled RGD-containing Glycopeptide and Positron Emission Tomography (2001) (0)
- Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer (2022) (0)
- TM-15GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO (2014) (0)
- FDG PET/CT for the evaluation of patients with thyroid associated orbitopathy (2007) (0)
- A Model of Experimental Kidney Irradiation for Screening of Response Modifiers: Evaluation of Insulin-like Growth Factor-1 (IGF-1) and Erythropoietin (EPO) (2005) (0)
- Value of PET imaging for radiation therapy* Wertigkeit der PET-Bildgebung für die Radioonkologie (2021) (0)
- Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma (2021) (0)
- Integrin αV Inhibition Reduces GvHD by Targeting inflammatory Neovascularization (2011) (0)
- Synthesis and Preclinical Evaluation of Ga-68-labeled Adnectin as a PET Agent for Imaging PD-L1 Expression (2020) (0)
- Future Directions The Move from Accuracy Studies to Randomized Trials in PET : Current Status and (2014) (0)
- Detection Efficacy of 18 F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2019) (0)
- Development of a novel high affinity Zr-89-Anticalin radiotracer directed against human CD98hc for diagnostic PET tumor imaging (2020) (0)
- Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients (2022) (0)
- Detection efficacy in 261 consecutive biochemical recurrent prostate cancer patients after radical prostatectomy using 18F-rhPSMA7 PET/CT imaging (2019) (0)
- Abstract B39: A pilot study of neuropsychological functions, APOE, and amyloid imaging in patients with gliomas (2018) (0)
- PO-0969 4D-PET/CT FOR TARGET VOLUME DELINEATION IN STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR MALIGNANT LUNG LESIONS (2012) (0)
- The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. (2022) (0)
- In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy (2021) (0)
- Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice. (2022) (0)
- Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma (2022) (0)
- 19 INVITED Application of Hypoxia Imaging in Radiation Treatment Planning (2011) (0)
- MP62-17 DIAGNOSTIC EFFICACY OF 18 F-RHPSMA-7.3 IMAGING FOR N-STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER (2020) (0)
- Monitoring bevacizumab therapy with PET/CT and 68Ga-NODAGA-c(RGDfK) (2013) (0)
- Quantitative and qualitative analysis of biodistribution and image quality of 18F- rhPSMA7 as novel radiohybrid PSMA-ligand (2019) (0)
- Nephrotoxicity after PSMA-RLT using Lu-177-PSMA I&T (2021) (0)
- [Monitoring of response to neoadjuvant therapy by positron emission tomography (PET)]. (2001) (0)
- Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer (2022) (0)
- Integrating respiratory gating and continuous bed motion PET/CT: evaluating an improved clinical workflow (2019) (0)
- qPSMA: First semi-automatic tool for whole-body tumor burden assessment in prostate cancer PET imaging and preliminary evaluation for PSMA-targeted radioligand therapy (2019) (0)
- Diagnostic efficacy of 18F-rhPSMA7 positron emission tomography for lymph node staging in patients with high-risk primary prostate cancer (2019) (0)
- Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (0)
- Influence of chemotherapy related genetic polymorphisms and FDG-PET on response and prognosis of locally advanced neoadjuvant treated adenocarcinomas of the esophagus (AEG I). (2006) (0)
- Lesion Detection Efficacy of F-18-rhPSMA-7.3 Positron Emission Tomography in Men with Biochemical Recurrence of Prostate Cancer: Initial clinical data from 285 consecutive Patients (2020) (0)
- Introduction (2011) (0)
- 99 METABOLIC PHENOTYPING WITH POSITRON EMISSION TOMOGRAPHY FOR PREDICTION OF TUMOR RESPONSE TO THE EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR ERLOTINIB (TARCEVA). (2007) (0)
- FDG avidity of metastatic thyroid cancer correlates with the presence of BRAF mutations (2014) (0)
- Characterization of a peridiaphragmatic artifact in 18F-FDG-PET/CT and its impact on quantitative analysis in cancer of the gastroesophageal junction (2011) (0)
- In vitro and in vivo imaging of irradiation induced changes in PARP1 expression in oral cancer cell lines (2016) (0)
- EP-1256 Influence of PET-imaging during treatment planning on outcome in meningioma patients (2019) (0)
- FDG-PET is more accurate than CT at assessing early treatment response to neoadjuvant therapy in soft tissue sarcomas (2008) (0)
- Preparation of 18F-labeled thymidine analogs using click chemistry (2006) (0)
- Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET (2018) (0)
- Quantification of glucose metabolic activity of human tumor xenografts in mice (2007) (0)
- Radiation treatment to the neck is significantly associated with diffusely increased thyroid FDG-uptake (2006) (0)
- Insulin-like growth factor-1 for amelioration and prevention of radiation-induced kidney dysfunction. (2005) (0)
- 18f-Rhpsma-7 Positron Emission Tomography (PET) for the Detection of Biochemical Recurrence after Primary Radiation Therapy of Prostate Cancer (2019) (0)
- Prediction o f R esponse t o P reoperative C hemotherapy i n Gastric C arcinoma b y M etabolic I maging: Results o f a P rospective T rial (2003) (0)
- MP09-16 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR THE DETECTION OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY (2019) (0)
- Correlation of 12 week PSA-response after 177Lu-PSMA radioligand therapy, baseline tumor burden and overall survival in mCRPC (2019) (0)
- Monitoring deoxyglucose treatment with FDG and FLT PET (2007) (0)
- PET imaging of recurrent brain tumors using 18F-FACBC (2019) (0)
- Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrent prostate cancer (2020) (0)
- Tumor glucose utilization predicts response to epidermal growth factor receptor kinase inhibitors (2006) (0)
- , PhD in Vivo PeT assay of Tumor glutamine Flux and Metabolism : InHuman Trial of 18 F-( 2 S , 4 R )-4-Fluoroglutamine 1 (2018) (0)
- 1116 POSTER The Influence of the Combined Treatment With Vadimezan (ASa 404) and Taxol on the Growth of U251 Glioblastoma Xenografts (2011) (0)
- Patterns of Inguinal Lymph Node Involvement in Anal Cancer - a Detailed PET-Imaging Based Analysis (2019) (0)
- Does a p53 Inhibitor Protect Mice Against the Toxicity of High-Dose Abdominal Radiotherapy? (2005) (0)
- 464 Molecular imaging of therapy response (2010) (0)
- 326: Positron Emission Tomography Using 11C-Choline in Urothelial Cancer (2004) (0)
- Changes in tumor invasiveness in response to src-kinase inhibition monitored by PET with radiolabeled RGD-peptides (2008) (0)
- C 16 Development and Preclinical Evaluation of the New Pan-Somatostatin PET Imaging Probe 68 Ga-DOTA-SOM 230 ( SOMscan ® ) (2012) (0)
- PET and PET-CT in Treatment Response Evaluation: Overview (2021) (0)
- Development of 64Cu- and 68Ga-somatostatin receptor antagonists for improved PET imaging (2011) (0)
- Tumor Imaging with Special Emphasis on the Role of Positron Emission Tomography in Radiation Treatment Planning (2009) (0)
- Using a CCK2R targeted near-infrared fluorescent probe to aid in intraoperative identification of loco-regional metastasis of medullary thyroid cancer (2014) (0)
- for Detection of Bone Marrow Involvement in Children and Adolescents With Hodgkin's Lymphoma (2011) (0)
- MP13-15 68GA-PSMA-11 PET/MPMRI FOR DETECTION OF PRIMARY PROSTATE CANCER IN PREVIOUSLY NEGATIVE-BIOPSIED MEN (2020) (0)
- Quantitative autoradiographic (QAR) evaluation of bombesin receptor (GRPR) expression in normal and malignant tissue (2014) (0)
- Radionuclide Therapy : A Pilot Study Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor (2014) (0)
- IMT-SPECT in gliomas: correlation with survival and consequences for target volume definition (2001) (0)
- EP-0991 MYOCARDIAL PERFUSION DEFECTS FOLLOWING RADIOTHERAPY FOR BREAST CANCER DETECTED BY 99MTC-MIBI-SPECT/CT (2012) (0)
- 18F-misonidazole Pet Tumor Hypoxia Imaging During Chemoradiation Therapy For HNSCC - Correlation To Outcome (2014) (0)
- Comparative analysis of various endpoints in in-vivo experiments in radiation-induced neural function disorder (2005) (0)
- How does the number of lesions analyzed impact response assessment with PERCIST in breast cancer (2015) (0)
- Monitoring Prostate Cancer Treatment Response to Radiation Therapy and Androgen Deprivation With Novel Radiolabeled and Dual-Labeled Gastrin-Releasing Peptide Receptor (GRPr) Antagonists. (2016) (0)
- 550IMT-spect and FDG-pet in the 3-D radiation treatment planning for gliomas (1996) (0)
- RADIATION-INDUCED DEFECTS IN MYOCARDIAL PERFUSION AFTER THERAPY FOR LEFT-SIDED BREAST CANCER EVALUATED WITH 99 MTC-MIBI-SPECT/CT (2011) (0)
- Preferred blood-brain transfer of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain (2007) (0)
- Feasibility of intraoperative fluorescence imaging of squamous cell carcinoma of the oral cavity using an optical PARP1 inhibitor (2015) (0)
- Positron E mission T omography i n N on-Small-Cell L ung Cancer: P rediction o f R esponse t o C hemotherapy b y Quantitative A ssessment o f G lucose U se (2003) (0)
- Abstract A062: Using CA19-9 as a translational biomarker for sLea targeted agents MVT-5873 and MVT-1075 in cancer (2018) (0)
- TU-C-217BCD-01: Where Molecular Imaging Is Taking Us (2012) (0)
- UvA-DARE ( Digital Academic Repository ) FDG PET and PET / CT : EANM procedure guidelines for tumour PET imaging : version 1 . 0 (2018) (0)
- The value of 18F-FDG PET as a predictor of survival in patients with gastro-oesophageal junction (GEJ) adenocarcinoma (2021) (0)
- OC-0386 A PET-based patterns of failure analysis in the context of contouring guidelines in anal cancer (2019) (0)
- 43 poster: Dynamics of Hypoxia in Head and Neck Cancer During Chemoradiotherapy Evaluated with [18]F-Fluoromisonidazole PET (2010) (0)
- The IR evolution in oncology : tools , treatments , guidelines The (2016) (0)
- Surveillance of Cancer Patients with Imaging: Self-Evident or Evidence-Based? (2013) (0)
- Correlation of 18F-DOPA PET to the genotype of paragangliomas and pheochromocytomas (2012) (0)
- Cell surface expression of an engineered antibody as a PET reporter gene for in vivo PET imaging (2008) (0)
- Improved pharmacokinetics of [18F]RGD‐peptides by serine‐conjugation (2001) (0)
- FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma (2011) (0)
- Molecular Imaging of Prostate Cancer 1 (2015) (0)
- Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer. (2006) (0)
- Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: A multicenter retrospective study. (2020) (0)
- O-(2-(F-18)fluorethyl)-L-tyrosin: A practicable aminoacid tracer for tumour volume definition by means of positron-emission-tomography in ZNS tumours (2005) (0)
- LB4 Positron emission tomography using carbon-11 choline (2004) (0)
- Accuracy of 18F-fluoroethyltyrosine PET for detecting high grade glioma recurrence: size matters (2020) (0)
- NCOG-16. A PILOT STUDY OF COGNITIVE FUNCTIONS, APOE AND AMYLOID IMAGING IN GLIOMA PATIENTS (2017) (0)
- An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (0)
- Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1) (2016) (0)
- CT-Based Radiomics Can Improve the Prediction of Recurrent Prostate Cancer-Positive Lymph Nodes (2019) (0)
- The Response of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Cell Lines on Standard Therapy and Treatment with an Experimental Alpha-Particle Emitter Immunoconjugate Targeting EGFR (Bi-213-Cetuximab) (2019) (0)
- 161 The assistance of PET and MRI in 3-D radiation treatment planning for primary brain tumors (1995) (0)
- A theranostic approach for CAR-T cell therapy. (2022) (0)
- [Molecular imaging in cancer therapy]. (2010) (0)
- Reply: Evidence-Based Assessment of PET in Germany (2012) (0)
- Prospective evaluation of FDG-PET for prediction of response and survival in AEG I/II (uT3cNany cM0) (2006) (0)
- The Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small Cell Lung Cancer (2014) (0)
- Imaging tumor metabolism after RET-inhibitor therapy: Towards an early readout of a novel treatment tool (2008) (0)
- Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. (2015) (0)
- Biological imaging in radiation treatment planning for brain tumours (2004) (0)
- Is response classification with PERCIST in stage IV breast cancer influenced by the number of lesions assessed (2015) (0)
- Glucose metabolic phenotyping and prediction of tumor grade in soft tissue and bone tumors by 18F-FDG PET imaging (2009) (0)
- Reproducibility of microPET and bioluminescence imaging in a xenograft model (2007) (0)
- Prediction of response to epidermal growth factor receptor kinase inhibitor (erlotinib) in advanced NSCLC by PET/CT: A prospective study (2008) (0)
- Evaluation of iPARP1 as an intraoperative imaging agent (2014) (0)
- Alterations of cortical glucose metabolism in limbic encephalitis resembling Alzheimer's disease on FDG PET (2009) (0)
- PO-0874: Development of a prognostic model for patients with high-grade meningioma - the ELSA study (2020) (0)
- Localizing sites of disease in patients with rising PSA up to 1 ng/mL following prostatectomy: how much information can conventional imaging provide? (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wolfgang Andreas Weber?
Wolfgang Andreas Weber is affiliated with the following schools: